M
Myriam M. Chaumeil
Researcher at University of California, San Francisco
Publications - 49
Citations - 2003
Myriam M. Chaumeil is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Isocitrate dehydrogenase & Mutant. The author has an hindex of 25, co-authored 44 publications receiving 1709 citations. Previous affiliations of Myriam M. Chaumeil include University of California, Berkeley & Temple University.
Papers
More filters
Journal ArticleDOI
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri,Michael De Lay,Liane M. Miller,W. Shawn Carbonell,Yu-Long Hu,Kan Lu,Maxwell W. Tom,Jesse Paquette,Taku Tokuyasu,Sean Tsao,Roxanne Marshall,Arie Perry,Kirsten Bjorgan,Myriam M. Chaumeil,Sabrina M. Ronen,Gabriele Bergers,Manish K. Aghi +16 more
TL;DR: Findings support the role of c-Met in survival in hypoxia and invasion, features associated with antiangiogenic therapy resistance, and growth and therapeutic resistance of xenografts resistant to antiangIogenic therapy.
Journal ArticleDOI
Noninvasive detection of target modulation following phosphatidylinositol-3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy
Christopher S. Ward,Humsa S. Venkatesh,Myriam M. Chaumeil,Alissa H. Brandes,Mark VanCriekinge,Hagit Dafni,Subramaniam Sukumar,Sarah J. Nelson,Daniel B. Vigneron,John Kurhanewicz,C. David James,Daphne A. Haas-Kogan,Sabrina M. Ronen +12 more
TL;DR: The application of hyperpolarized (13)C MRS of pyruvate to monitor alterations in LDHA activity and expression caused by PI3K pathway inhibition is illustrated, showing the potential of this method for noninvasive imaging of drug target modulation.
Journal ArticleDOI
Lactate dehydrogenase A silencing in IDH mutant gliomas.
Charles Chesnelong,Myriam M. Chaumeil,Michael D. Blough,Mohammad Al-Najjar,Owen Stechishin,Jennifer A. Chan,Russell O. Pieper,Sabrina M. Ronen,Samuel Weiss,H. Artee Luchman,J. Gregory Cairncross +10 more
TL;DR: It is demonstrated that LDHA was silenced in IDH(mt) derived BTSCs, including those that did not retain the mutant IDH1 allele (mIDH(wt), matched BTSC xenografts, and parental glioma tissues, and this is the first demonstration of downregulation of LDHA in cancer.
Journal ArticleDOI
Non-invasive in vivo assessment of IDH1 mutational status in glioma
Myriam M. Chaumeil,Peder E. Z. Larson,Hikari A. I. Yoshihara,Olivia M. Danforth,Daniel B. Vigneron,Sarah J. Nelson,Russell O. Pieper,Joanna J. Phillips,Sabrina M. Ronen +8 more
TL;DR: It is shown that [1-(13)C] α-ketoglutarate can serve as a metabolic imaging agent for non-invasive, real-time, in vivo monitoring of mutant IDH1 activity, and can inform onIDH1 status.
Journal ArticleDOI
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Jose L. Izquierdo-Garcia,Pavithra Viswanath,Pia Eriksson,Larry Cai,Marina Radoul,Myriam M. Chaumeil,Michael D. Blough,H. Artee Luchman,Samuel Weiss,J. Gregory Cairncross,Joanna J. Phillips,Russell O. Pieper,Sabrina M. Ronen +12 more
TL;DR: It is established that the IDH1 mutation induces an MRS-detectable reprogramming of pyruvate metabolism, which is essential for cell proliferation and clonogenicity, with immediate therapeutic implications.